World Ophthalmic Pharmaceutical Drugs Market to Reach $12.86 Billion by 2010, According to New Report by Global Industry Analysts
San Jose, California (PRWEB) April 24, 2008 -- Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries. And increased healthcare spending in these countries is creating a strong demand for advanced ophthalmic therapeutic treatments. This in turn is leading to the rise in investments in ophthalmic drug research, and a parallel spurt in the commercial availability of innovative and promising ocular drugs. Ongoing research studies on developing pharmacologic IOP reducing drugs is expected to lead to the availability of powerful topical drugs with lesser side effects, and higher therapeutic efficacies, thereby overthrowing the present bottleneck of low patient compliance. Pharmacodiversity and newer classes of potent drugs together, are expected to encourage patient compliance, and improve patient outcomes. The market therefore is expected to get a much-awaited respite from the business, and economic repercussions of low patient compliance.
Developing countries in Asia-Pacific, and Latin America offer ample opportunities for future growth, given the widespread prevalence of ocular diseases in these countries. Malnutrition, higher incidence of HIV, contaminated water, and pollution, rank among the numerous factors responsible for aggravating ophthalmic diseases in developing countries. Shifting demographics additionally extend expanded market opportunities. Disease segments with a clear market potential, and which offer abundant opportunities for drug research initiatives, include Cataracts, Myopia, diabetic retinopathy, Dry AMD, and Neuroprotection in glaucoma, Back of Eye diseases and Dry eye, among others.
As stated by the recent report published by Global Industry Analysts, Inc., world market for ophthalmic pharmaceutical drugs (http://www.strategyr.com/Opthalmic_Pharmaceutical_Drugs_Market_Report.asp) is forecast to grow at a CAGR of 4.37% over the years 2011 through 2015. Anti-Allergy Drugs Market (http://www.strategyr.com/Opthalmic_Pharmaceutical_Drugs_Market_Report.asp) in Asia-Pacific is projected to reach $149.64 million by the year 2012, while drugs for Back of Eye Diseases (http://www.strategyr.com/Opthalmic_Pharmaceutical_Drugs_Market_Report.asp) in Latin America is projected to reach $219.01 million by the year 2015. Japanese back of the eye drugs market is forecast to grow at the fastest CAGR of 16.89% over the years 2011 through 2015.
Leading global and regional players operating in the industry include Akorn Inc, Alcon Eye Care Inc, Allergan Inc., Alimera Sciences Inc, Bausch & Lomb Inc, Genvec Inc, Glaxosmithkline Plc, Inspire Pharmaceuticals Inc, Ista Pharmaceuticals Inc, Merck & Co. Inc, Novartis Ophthalmics, Opko Health Inc, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc, QLT Inc., Santen Pharmaceutical Co., Ophthotech Corporation, and Fougera, among others.
The report titled "Ophthalmic Pharmaceutical Drugs: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of ophthalmic drugs, delivery technologies, market drivers, issues, and challenges. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key therapeutic areas. Ophthalmic therapeutic markets analyzed in the report include Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, and Back of Eye. Latent demand patterns are quantified across major geographic market verticals including the United States, Canada, Japan, France, Germany, United Kingdom, Spain, Asia-Pacific, and Latin America, among others. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.
For more details about this research report, please visit
http://www.strategyr.com/Opthalmic_Pharmaceutical_Drugs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site www.StrategyR.com
###
Related Articles:
Avandia, Other Drugs, Not Only Option For Treating Diabetes
ImTypeFree.com, a diabetes health education website, announces that the management of Type 2 Diabetes through nutrition and exercise may be the best treatment.
Are People Who Take Drugs Accessing The Astral Plane?
It depends on the drugs, but if altered perception is involved then to a certain degree the answer is yes However, for several reasons it is detrimental and definitely not recommended
LegalView Posts Findings That Anti-Inflammatory Drugs May Be Capable of Treating Mesothelioma
LegalView recently reported the use of non-steroidal anti-inflammatory drugs (NSAIDs) may have the ability to treat a variety of human cancers, including mesothelioma. A study released in the Journal of Translational Medicine reported that the NSAIDs may be responsible for anti-tumoral activity on mesothelioma cells.
Over Medication; Grandma is on Drugs
It is very interesting this hypochondriac attitude which permeates our society? The power of suggestion is alive and well? "Do not feel good today, take a drug?" Oh that made you feel a different way? Take another drug? Oh those two together caused another feeling you do not like, my oh my, here is a third drug? You know these tests prove conclusive that this is not working and something is wrong, we should try this other drug too? Crazy, are you buying all this.I remember visiting my grandmother's friend who had a drug regiment, she took something like 13 different pills some every 4 hours, some every six, some every 8, one every twelve and the rest once per day? My gosh, I was surprised she could even keep up with all this.
The Truth about C Reactive Protein and Cholesterol Lowering Drugs
You might disagree, but hear me out on this..
World Ophthalmic Pharmaceutical Drugs Market to Reach $12.86 Billion by 2010, According to New Report by Global Industry Analysts
Driven by the aging world population, and commensurate advancements in ophthalmic drug delivery techniques, the world ophthalmic pharmaceutical drugs market is projected to reach $12.86 billion by the year 2010. Rapid drug development, and the resulting spurt in new drug availability, together with the age driven rise in ophthalmic disorders, and pollution-induced susceptibility to ocular allergies, are together expected to contribute towards the overall growth of the market. Innovative breakthroughs in transporter/receptor mediated, eye focused drug delivery, and developments made in the area of ocular bioadhesives, and penetration enhancers, will all help ensure the market's future growth and sustenance.
Natural Alternatives vs. Prescription Drugs
Natural Alternatives: A growing phenomenon across this world which is a very diverse concept yet very divine and instrumental in healing health diseases. It might be thought as any health care which is not a part of the mainstream medical establishment.
Cholesterol Reducing Vitamins And Drugs
Take in an oddly prominent cholesterol step vase rest lone at peril of increasing mind ailment It will not be an instant thing; sympathy illness can slowly but surely enlarge as a one epoch and as one continue to keep up a very tall cholesterol echelon